CLYM - NASDAQ

Climb Bio, Inc.

CLYM·NASDAQ

$10.91

-2.6%

HealthcareBiotechnology

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$743.89M

EPS-0.8800

P/E Ratio-12.40

Earnings Date08/11/2026

clym

Other Current Liabilities

Last Annual Value

2.57M

3-Year CAGR

5-Year CAGR

36%

10-Year CAGR

Adjust for Inflation

Climb Bio, Inc. Competitors Analysis of Other Current Liabilities

CLYM · NASDAQ

Company	Other Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Climb Bio, Inc. NASDAQ:CLYM	2.57M	165.0%	N/A	N/A
Inovio Pharmaceuticals, Inc. NASDAQ:INO	36.44M	54.2%	12.0%	16.2%
Spero Therapeutics, Inc. NASDAQ:SPRO	5.58M	20.1%	N/A	4.2%
Turn Therapeutics Inc. NASDAQ:TTRX	3.03M	86.8%	N/A	N/A
Agenus Inc. NASDAQ:AGEN	83.11M	-16.2%	1.9%	29.3%
Anixa Biosciences, Inc. NASDAQ:ANIX	922.00K	N/A	N/A	N/A
Seres Therapeutics, Inc. NASDAQ:MCRB	4.57M	-57.4%	-26.4%	N/A
Cognition Therapeutics, Inc. NASDAQ:CGTX	11.99M	117.5%	37.1%	N/A
Context Therapeutics Inc. NASDAQ:CNTX	5.38M	101.1%	128.9%	N/A
TuHURA Biosciences, Inc. NASDAQ:HURA	5.72M	246.9%	65.8%	67.4%
Inhibikase Therapeutics, Inc. NASDAQ:IKT	7.14M	124.0%	N/A	N/A

Climb Bio, Inc. Fair Value Envelope

CLYM · NASDAQ

Our analysis suggests that CLYM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.91, this represents a potential HIDDEN relative to our calculated worth for Climb Bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $10.91

Related Guides

Blog Categories

Continue your CLYM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.